Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Common Stock Issued

Cash raised by issuing new shares.

Pelthos Therapeutics Inc.AMEX: PTHS

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow grows to $0

Q1 FY2026 common stock issued was $0, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $27.59M.

Context

  • Common stock issued amounted to 164.3% of revenue in FY2025.
  • Common stock issued increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $0 or moves back toward the trailing-twelve-month quarterly average of $6.9M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$27.59M+355.7% YoY
LTMMar 2026
$27.59M+33293.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+355.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
27.59M USD
Year-over-year change
+355.7%

Common Stock Issued vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 common stock issued of $27.59M is the 2nd largest of the 4 companies compared; the peer median is $11.01M.
  • Its year-over-year change of +33293.9% is the highest of 4, against a peer median of +70.1%.
  • Common stock issued amounts to 99.6% of revenue for PTHS.
PTHS Competitors Peer median
Common Stock Issued for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CINGCingulate Inc.LTM Mar 2026$30.15M +68.4%——
PTHSPelthos Therapeutics Inc.LTM Mar 2026$27.59M +33293.9%—99.6%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$11.01M +70.1%+310.6%—
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$9.4M +927.8%+26.1%—
Peer median (excluding PTHS) $11.01M+70.1%+168.3%—

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.46M)(7.38M)(7.96M)(43.32M)
Depreciation & Amortization0002.36M
Deferred Income Tax0000
Stock-Based Compensation110.15K1.73M1.8M0
Change in Working Capital640.86K2.05M34.63K(6.07M)
Accounts Receivables00(45.79K)(8.81M)
Inventory0001.78M
Accounts Payables413.6K1.63M1.18M1.36M
Other Working Capital227.26K424.07K(1.1M)(395K)
Other Non-Cash Items140.43K2.62M328.93K24.44M
Operating Cash Flow(1.57M)(981.03K)(5.79M)(22.59M)
Capital Expenditures000(99K)
Acquisitions (Net)000(5.14M)
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow000(5.24M)
Debt Repayment400K766.94K321.43K17.75M
Common Stock Issued0255.41K6.05M27.59M
Common Stock Repurchased00(166.51K)0
Dividends Paid0000
Other Financing Activities1.22M000
Financing Cash Flow1.62M1.02M6.21M45.34M
Effect of Forex Changes000(443)
Net Change in Cash55.07K41.32K417.05K17.51M
Free Cash Flow(1.57M)(981.03K)(5.79M)(22.69M)

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.